Showing 1 - 10 of 1,199
public interest aspect and human rights implications while granting injunctions in patent litigation. Moreover, it asserts … that the courts should exercise prudence in granting injunctive relief in cases involving patent infringement, and take …
Persistent link: https://www.econbiz.de/10014494919
Persistent link: https://www.econbiz.de/10014374380
Persistent link: https://www.econbiz.de/10014374515
Vor dem Hintergrund der weiter wachsenden Bedeutung der Volksrepublik China in der Weltwirtschaft beschäftigt sich die Arbeit mit dem dortigen Schutz von Patenten. Das chinesische Patentsystem entspricht dem internationalen Standard des TRIPS-Übereinkommens. Die Analyse von Patentanmeldungen...
Persistent link: https://www.econbiz.de/10010303790
intellectual property rights, particularly patent rights, in restricting access by enabling pharmaceutical market monopolies that … manufacturers to seek regulatory approval before a patent expires, thus preventing the de facto extension of patent monopolies. The …
Persistent link: https://www.econbiz.de/10015325508
, this paper concludes that second medical uses do not qualify per se for patent protection and have only been protected in … from strategic patent filing from pharmaceutical companies to extend the life of existing patents, justified mainly for … medicines and the public health, in particular in developing countries. Therefore, this paper argues that a sound patent policy …
Persistent link: https://www.econbiz.de/10012490877
In this paper, we ask whether courts should continue to rule settlements in the context of pharmaceutical claims per se legal, when these settlements comprise payments from originator to generic companies, potentially delaying generic entry compared to the underlying litigation. Within a...
Persistent link: https://www.econbiz.de/10010427644
Persistent link: https://www.econbiz.de/10011292202
Competition law may play an important role in drug pricing control by containing high prices derived from economic violations. Since the use of competition tools is not limited by the TRIPS Agreement or other international binding disciplines, there is ample policy room to explore how countries,...
Persistent link: https://www.econbiz.de/10013330841